Type I Diabetes Mellitus Clinical Trial
Official title:
A 28-week, Prospective, Single-arm, Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mL in Combination With Prandial Rapid-acting Insulin Analogue in Patients With Type 1 Diabetes Previously Uncontrolled on Twice-daily Basal Insulin as Part of Basal-bolus Therapy
Primary Objective: To evaluate the efficacy of switching treatment from twice-daily basal insulin to once-daily insulin glargine (U300) as part of basal bolus regime in terms of glycated hemoglobin improvement (reduction by at least 0.3%), in uncontrolled type 1 diabetes mellitus patients. Secondary Objectives: - To evaluate other efficacy parameters in terms of glycemic control as well as safety including hypoglycemia events, weight changes, and adverse events. - To evaluate the effect of insulin glargine (U300) on diabetes treatment satisfaction and fear of hypoglycemia as well as patient's satisfaction regarding the number of daily injections.
The estimated average study duration is 29 weeks, including run-in period of 4 weeks; treatment period of 24 weeks, and follow-up period of 1 week. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01467063 -
Glutamine and Insulin Sensitivity in Type I Diabetes
|
N/A | |
| Completed |
NCT01868594 -
Clinical Trial of Efficacy and Safety of Subetta in the Combined Treatment of Patients With Type I Diabetes Mellitus
|
Phase 4 | |
| Completed |
NCT01552603 -
Artificial Pancreas Control System in an Inpatient Setting
|
Phase 2 | |
| Not yet recruiting |
NCT02126605 -
Accuracy of Blood Glucose Detection by Diabetes Alert Dogs
|
N/A |